Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
09 January 2024 - 1:00AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced preliminary, unaudited revenue
results for the full year ended December 31, 2023.
Cytek expects its full year revenue for 2023 to be near the high
end of the company’s most recent revenue guidance range of $188
million to $192 million, provided on November 9, 2023.
The preliminary financial results in this press release are not
a comprehensive statement of Cytek’s financial results for the year
ended December 31, 2023 and have not been audited, reviewed or
compiled by its independent registered public accounting firm.
Cytek’s actual revenue may differ from the estimate due to the
completion of the Company’s year-end closing and auditing
procedures and are therefore subject to adjustment. Cytek plans to
report financial results for the fourth quarter and full year ended
December 31, 2023 and to provide 2024 financial guidance during its
earnings call expected to be held at the end of February 2024.
J.P. Morgan Healthcare Conference
Cytek is providing these updates in advance of its participation
in the 42nd Annual J.P. Morgan Healthcare Conference,
which begins today in San Francisco, CA. CEO Wenbin Jiang is
scheduled to present and participate in a Q&A session on
Thursday, January 11, 2024, at 8:15 a.m. Pacific Time / 11:15 a.m.
Eastern Time. Interested parties may access a live and archived
webcast of the presentation on the “Investors” section of the
company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis
solutions company advancing the next generation of cell analysis
tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; and reagents, software and
services to provide a comprehensive and integrated suite of
solutions for its customers. Cytek is headquartered in Fremont,
California with offices and distribution channels across the globe.
More information about the company and its products is available
at www.cytekbio.com.
Cytek’s products are for research use only and not for use in
diagnostic procedures (other than Cytek’s Northern Lights-CLC
system and certain reagents, which are available for clinical use
in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern
Lights, Amnis and Guava are trademarks of Cytek Biosciences,
Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. All statements, other than statements of historical
facts, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,” “might," "will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negatives of these
terms or variations of them or similar terminology, but the absence
of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s expected revenue for the full year
ended December 31, 2023. Cytek’s audited financial results for the
full year ended December 31, 2023 are not yet available and its
preliminary expectations regarding revenue for the period are
subject to review by Cytek’s management and audit by Cytek’s
independent registered public accounting firm. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management.
These statements also deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include adjustments to the estimate that may
be required in connection with the completion of the Company’s
year-end closing and auditing procedures. You should refer to the
section entitled “Risk Factors” set forth in Cytek’s most recent
Quarterly Report on Form 10-Q filed with the SEC on November 14,
2023 and other filings Cytek makes with the SEC from time to time
for a discussion of important factors that may cause actual results
to differ materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead of Investor
RelationsCytek Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From May 2024 to Jun 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Jun 2023 to Jun 2024